Your browser doesn't support javascript.
loading
Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study.
Down, Susan; Alzaid, Aus; Polonsky, William H; Belton, Anne; Edelman, Steven; Gamerman, Victoria; Nagel, Friederike; Lee, Jisoo; Emmerson, James; Capehorn, Matthew.
Afiliação
  • Down S; Somerset Partnership NHS Foundation Trust, Parkgate House, East Reach, Taunton, Somerset TA1 3ES, United Kingdom. Electronic address: Su.Down@sompar.nhs.uk.
  • Alzaid A; Prince Sultan Military Medical City, PO Box 7897, Riyadh 11159, Saudi Arabia. Electronic address: drausalzaid@hotmail.com.
  • Polonsky WH; Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Behavioral Diabetes Institute, 5405 Oberlin Drive, Suite 100, San Diego, CA 92121, USA. Electronic address: whp@behavioraldiabetes.org.
  • Belton A; The Michener Institute of Education at UHN, 222 St. Patrick Street, Toronto, Ontario M5T 1V4, Canada. Electronic address: ibelton@telus.net.
  • Edelman S; Division of Endocrinology and Metabolism, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Veterans Affairs Medical Center, 3350 La Jolla Village Dr, San Diego, CA 92161, USA. Electronic address: svedelman@vapop.ucsd.edu.
  • Gamerman V; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877, USA. Electronic address: victoria.gamerman@boehringer-ingelheim.com.
  • Nagel F; Boehringer Ingelheim GmbH, Binger Straße 173, D-55216 Ingelheim am Rhein, Germany. Electronic address: friederike.nagel@boehringer-ingelheim.com.
  • Lee J; Boehringer Ingelheim International GmbH, Binger Straße 173, D-55216 Ingelheim am Rhein, Germany. Electronic address: jisoo.lee@boehringer-ingelheim.com.
  • Emmerson J; Boehringer Ingelheim International GmbH, Binger Straße 173, D-55216 Ingelheim am Rhein, Germany. Electronic address: james.emmerson@boehringer-ingelheim.com.
  • Capehorn M; Rotherham Institute for Obesity, and Clifton Medical Centre, Doncaster Gate, Rotherham, South Yorkshire S65 1DA, United Kingdom. Electronic address: mcapehorn@yahoo.co.uk.
Diabetes Res Clin Pract ; 148: 179-188, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30641173
ABSTRACT

AIMS:

Physician-patient communication when discussing the need for additional oral medication for type 2 diabetes (add-on) may affect the self-care of people with this condition. We aimed to investigate physicians' recalled experiences of the add-on consultation.

METHODS:

We conducted a cross-sectional survey of physicians treating people with type 2 diabetes in 26 countries, as part of a large cross-national study of physician-patient communication during early treatment of type 2 diabetes (IntroDia®). The survey battery included novel questions about physician experiences at add-on and the Jefferson Scale of Physician Empathy.

RESULTS:

Of 9247 eligible physicians, 6753 responded (73.0% response rate). Most (82%) agreed that physician-patient discussions at add-on strongly influence patients' disease acceptance and treatment adherence. Half the physicians reported ≥1 challenge in most or all add-on conversations, with a significant inverse relationship between frequency of challenges and Jefferson Scale of Physician Empathy score (standardised ß coefficient -0.313; p < 0.001). Physicians estimated that only around half their patients with type 2 diabetes follow their self-care advice. Exploratory factor analysis of physician beliefs about why their patients did not follow recommendations yielded two distinct dimensions psychosocial barriers (e.g. depressed mood) and personal failings of the patient (e.g. not enough willpower) (r = 0.37, p < 0.001).

CONCLUSIONS:

Physicians' empathy and beliefs about their patients may play a significant role in their success with the add-on conversation and, consequently, promotion of patient engagement and self-care. Although the study was limited by its retrospective, cross-sectional nature, the findings from IntroDia® may inform efforts to improve diabetes care.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Relações Médico-Paciente / Médicos / Comunicação / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Res Clin Pract Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Relações Médico-Paciente / Médicos / Comunicação / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Res Clin Pract Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2019 Tipo de documento: Article